Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space
Otsuka Pharmaceuticals recently announced that the FDA has accepted for review the biologics licence application (BLA) for sibeprenlimab. Sibeprenlimab acts…
Otsuka Pharmaceuticals recently announced that the FDA has accepted for review the biologics licence application (BLA) for sibeprenlimab. Sibeprenlimab acts…
Breast cancer (BC) is the most prevalent cancer among women globally with two million diagnosed cases each year. Oestrogen receptor…
22 May 2025 saw the announcement that two highly anticipated trials would have presentations at the 2025 Annual Meeting of…
Endometriosis is a condition that affects 10%–15% of women of childbearing age, in which elements of the endometrium develop outside…
Ionis Pharmaceuticals has reported positive topline results from the ESSENCE study evaluating olezarsen in individuals with moderate hypertriglyceridemia who are…
On 19 May 2025 at the American Thoracic Society (ATS) International Conference held in San Francisco, AstraZeneca presented results from…
Member states of the World Health Organization (WHO) have recently agreed on the world's first Pandemic Agreement. This landmark decision…
On 18 May at the 2025 American Thoracic Society (ATS) International Conference, AstraZeneca presented results on its interleukin-33 (IL-33) inhibitor,…
According to the British Academy of Audiology, hearing loss (HL) is the second most common disability in the UK, affecting…
People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive episodes than manic…